The aims of this study were to retrospectively review Japanese consecutive cases of @entity6558 ( @entity6558 ), @entity6017 ( @entity6017 ), and clinically @entity8817 ( @entity195 ), focusing on @entity358 ( @entity358 ) and @entity5 , and to document any differences in the incidence, clinical features, and impact on prognosis among @entity1 with @entity6558 , @entity6017 , and @entity195 . We retrospectively reviewed 62 consecutive @entity1 diagnosed with @entity6558 , @entity6017 , and @entity195 according to Bohan and @entity14417 ( @entity6558 / @entity6017 ) and Sontheimer's @entity195 ( @entity195 ), focusing on @entity358 and @entity5 . @entity358 occurrence rates were 48  % (11/23) in @entity1 with @entity6558 , 46  % (11/24) in @entity6017 , and 100  % (15/15) in @entity195 . @entity5 occurred during diagnosis or the observation period in 14 @entity1 ; 86  % were without @entity358 , and 64  % were @entity6017 without @entity358 . Multivariate logistic regression analysis showed that the risk of newly diagnosed @entity5 was significantly lower in @entity1 with @entity358 [odds ratio, 0.0688; 95  % confidence interval (CI), 0.00127-0.372; p   =   0.00190] and significantly higher in @entity1 with @entity6017 (odds ratio, 5.21; 95  % CI, 1.17-23.1; p   =   0.0299) than in other @entity1 . @entity1 with @entity5 had shorter survival than those without @entity5 ; no clinically meaningful difference in survival was observed among the different @entity5442 types and for presence of @entity358 . In @entity358 , 80  % fatal cases died from refractory @entity358  <=90  days from the first visit; neither @entity204 nor recurrence occurred subsequently. In conclusion, a positive association between @entity6017 and @entity5 and a negative association between @entity358 and @entity5 were noted. In the present study, @entity5 was a predictor of poor long-term prognosis, but @entity358 were not. @entity358 associated with @entity195 contributed greatly to poor short-term prognosis, but neither @entity204 nor recurrence occurred subsequently.

Incidence and impact of interstitial lung disease and @entity5 in @entity1 with @entity6558 , XXXX , and clinically @entity8817 : a retrospective cohort study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6017 :: ('MESH:D003882', 'Disease') :: ['dermatomyositis', 'DM'] @entity5442 :: ('MESH:D009220', 'Disease') :: ['myositis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy', 'malignancies', 'Malignancy'] @entity8817 :: ('MESH:C538250', 'Disease') :: ['amyopathic dermatomyositis'] @entity14417 :: ('MESH:C537884', 'Disease') :: ["Peter's criteria"] @entity358 :: ('MESH:D008171', 'Disease') :: ['ILD', 'interstital lung disease', 'CADM-ILD'] @entity195 :: ('MESH:D000544', 'Disease') :: ['CADM', "criteria and Gerami's criteria"] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity6558 :: ('MESH:D017285', 'Disease') :: ['PM', 'polymyositis']
@entity6017 :: (MESH:D003882,Disease) :: ['dermatomyositis']
